R Squared’s Foghorn Therapeutics FHTX Stock Holding History

R Squared’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30	Closed	-$142	–	705
2024 Q4	$142	Buy	+30	New	+$219	﹤0.01%	1565

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R Squared's FHTX Position: Q1 2025 in Review

R Squared sold out of Foghorn Therapeutics (FHTX) in Q1 2025, closing a stake of 30 shares — an estimated $142 sold.

R Squared first reported a position in FHTX in Q4 2024 and held it in 1 quarter. The position peaked at $142 in Q4 2024. 90 funds tracked by Wall St. Rank hold FHTX as of Q1 2025.

R Squared reported no remaining Foghorn Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 30 Foghorn Therapeutics shares in Q1 2025, an estimated $142.
R Squared first reported a position in Foghorn Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Foghorn Therapeutics position peaked at $142 in Q4 2024.
90 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.